Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00936858 · ClinicalTrials.gov registry record · Phase 2
RAD001 for Patients With Radioiodine Refractory Thyroid Cancer
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT00936858 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 50 participants.
The verdict
NCT00936858, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
Since thyroid cancer becomes refractory to radioactive iodine, treatment options are very limited. Tyrosine kinase inhibitors such as sorafenib have recently shown promise. This trial seeks to expand treatment options for this disease with a new, oral drug called RAD001. It is an inhibitor of the mTOR pathway and has shown activity in neuroendocrine cancers of the gastrointestinal tract and has been approved for the treatment of metastatic renal cell cancer.
Interventions
- DRUG RAD001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2009-07 |
| Est. Completion | 2020-02-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00936858
The ClinicalTrials.gov registry entry for NCT00936858 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RAD001 is the first listed.
NCT00936858 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00936858 about?
NCT00936858 is a clinical study titled "RAD001 for Patients With Radioiodine Refractory Thyroid Cancer". Since thyroid cancer becomes refractory to radioactive iodine, treatment options are very limited. Tyrosine kinase inhibitors such as sorafenib have recently shown promise. This trial seeks to expand treatment options for this disease with a new, oral drug called RAD001. It is an inhibitor of the mT...
What is the current status of trial NCT00936858?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2009-07. Estimated completion is 2020-02-27.
What interventions are being tested in trial NCT00936858?
The interventions under investigation include: RAD001 (DRUG).
Who is sponsoring clinical trial NCT00936858?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.